Last reviewed · How we verify

NCT04956198

Drug Sensitivity and Mutation Profiling

Completed Last updated 14 February 2023
What this trial tests

trial in Ewing Sarcoma in 14 participants. Completed in 31 December 2022.

Timeline
17 November 2020
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorFlorida International University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment14
Start date17 November 2020
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across United States

Conditions studied

Sponsor

Florida International University

Who can join

Under 21, any sex, with Ewing Sarcoma or Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (DST). In addition, the genetic profile of the tumor will be obtained from the medical records and correlated with drug response.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Functional personalized complex combination nano therapy for osteosarcoma.
    Bar-Natan O, Harris Y, Sason H, Shamay Y. · · 2025 · cited 2× · PMID 41102354 · DOI 10.1038/s41598-025-20222-3

Verify or expand the search:

Other recruiting trials for Ewing Sarcoma

Currently open trials in the same condition.

Other Florida International University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04956198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing